Combined NMR metabolomics and glycomics blood test improves cancer detection in patients with non-specific symptoms

A prospective study of 369 patients with non-specific symptoms found that integrating glycomics with NMR metabolomics achieved an AUC of 0.814 for cancer detection, with a refined subgroup AUC of 0.884. A two-dimensional risk-projection model reached 89.2% accuracy for cancer cl…

• The SCAN2 study validated a metabolomic signature in a real-world cohort of 369 patients (59 with cancer) presenting with non-specific symptoms.
• A machine-learning classifier distinguishing metastatic from non-metastatic disease achieved an AUC of 0.80.
• This was a single-center prospective observational study; the model has not been externally validated.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.